Q: What is Neuraxpharm’s value proposition and how does it differentiate the company within the field of central nervous system (CNS) disorders?
A: Neuraxpharm is a Spanish-German company that arrived in Mexico two years ago. We are opening offices outside the European Union, and Mexico is the first subsidiary to be established beyond that region. We will open one in Brazil in a few months.
We fully specialize in the central nervous system, and are a leader in the European Union in both generic and innovative products. We have more than 130 molecules in our portfolio. By opening this subsidiary in Mexico, we aim to consolidate the Neuraxpharm name so psychiatrists and neurologists can access the best treatments. In Mexico, we have launched three brands and plan to release two more next year. By 2027, we expect to introduce three innovative products that will strengthen the country’s prescribing portfolio.
Q: What opportunities has Neuraxpharm identified in the Mexican market?
A: Mexico has always been an attractive market. When our International Business division was created, the main brands acquired from other laboratories already had a strong presence in the country, which made it easier to transfer operations. The Mexican market also has significant value and potential for growth. After consolidating operations here, we will open Brazil, followed by other Latin American subsidiaries from 2026 onward.
We have three strategies to grow the company. The first involves acquiring brands from other laboratories, which is how we opened the subsidiary. These were mature brands and two of them do not have generic versions, so we are practically unique in the market. The second path, which has been the most complex and demanding, is launching the molecules we already have in Spain, Germany, and other parts of the European Union in Mexico. This process depends on COFEPRIS and other regulatory alignments. The third is developing proprietary brands locally.
We do not manufacture in Mexico. From submitting our first registration to COFEPRIS to consolidating our office and building our own sales force, it has been a long but enriching process. Little by little, physicians are starting to recognize Neuraxpharm.
Q: What has been your approach to engaging with Mexican healthcare professionals?
A: Physicians often have their preferred products to which they remain loyal. However, the country’s main opinion leaders already knew of the Neuraxpharm brand and its reputation in the European Union, and want to access these products in Mexico. The overall reception has been positive. We are officially presenting ourselves for the first time at the upcoming Psychiatry Congress, which marks our formal debut within the central nervous system field.
Q: What are the main challenges you have identified in Mexico regarding access to treatment?
A: Disorders such as anxiety, depression, psychosis, and schizophrenia are among the most common. We also see a high prevalence of dementia and sleep disorders like insomnia, which are linked to our fast-paced lifestyles, especially in urban settings such as Mexico City. Many people experience anxiety or sleep issues at some point; not all require pharmacological treatment, but these conditions are increasingly frequent. Good sleep hygiene can help, though in some cases, medical intervention is necessary.
Everyone should, at some point, consult a psychiatrist or a psychologist as part of maintaining mental health. We must also remove the stigma as these are not “bad” or “taboo” conditions; they are simply part of human health. There is no specific age for mental health disorders. Many have neurological or chemical origins and can appear at any time. Anxiety and depression often begin at younger ages and may persist if untreated. Unfortunately, women are more prone to conditions such as depression, including postpartum depression.
Q: What measures are necessary to increase awareness and prevention of these diseases?
A: There is still much room to raise awareness and promote prevention of central nervous system disorders, and many other medical specialties. There are about 10 patients for every psychiatrist in Mexico. General practitioners play a key role in identifying and referring cases. We also need to normalize the use of anxiolytics or antidepressants. Patients often feel ashamed or afraid to discuss their prescriptions, when in fact it should be treated as any other health issue.
Q: What projects is Neuraxpharm driving in the treatment of multiple sclerosis?
A: Multiple sclerosis is one of the most complex diseases. In the European Union, Neuraxpharm has launched an antibody-based treatment taken only once per month to control the disease. This marks a major difference compared with other treatments that require more frequent dosing. We are working to bring this innovation to Mexico, though timelines depend on regulatory advances. This type of product represents the future of treatment for multiple sclerosis. These monoclonal antibodies are key to controlling, though not necessarily eradicating, the disease.
Q: How is Neuraxpharm transforming the CNS healthcare field?
A: Innovation is one of our company’s main pillars. In the European Union, we have products designed to improve patient adherence and ease of administration. Our goal is to introduce to Mexico these medications, which include single-dose or divisible tablets that simplify treatment regimens and reduce pill burden.
Beyond reformulation, we also invest in R&D for new molecules. Our research centers, primarily in Germany, focus on developing advanced therapies for central nervous system disorders. Innovation defines who we are.
Q: How do partnerships with the medical community and patient associations contribute to strengthening the neurological care ecosystem in Mexico?
A: We cannot operate in isolation. Collaboration is essential, so we aim to create strategic alliances that ultimately benefit patients and physicians alike. Our first partnership in Mexico was with the Mexican Psychiatric Association (APM). We hope to strengthen relationships with other associations and eventually with patient advocacy groups, since their participation is key to improving quality of life and advancing mental health awareness in Mexico.
Q: What are Neuraxpharm’s medium-term objectives and priorities to consolidate its presence across Latin America?
A: First, we aim to consolidate our portfolio and reposition our three mature brands in the minds of physicians. Second, our two product launches next year must be successful. Third, we must expand our reach among medical professionals to increase awareness. If we achieve these three goals by the end of 2026, we will consider it a successful year.
One of the upcoming launches involves an innovative pharmaceutical and the other is a generic product. Our focus is on ensuring quality and patient adherence, as both aspects are critical for success. Our goal is to reciprocate the physicians’ trust by consolidating the Neuraxpharm brand in Mexico and offering high-quality products. We are here for the long term. Our intention is to form genuine alliances, not just transactional relationships, and to work together for better mental health outcomes. If patients are mentally well, physicians gain their trust, the company meets its objectives, and together we strengthen this ecosystem of confidence. That is the true measure of success.
Neuraxpharm is a leading specialty pharmaceutical company that focuses on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years.
link